These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 34298159)

  • 21. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
    Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabrafenib Effective in Pediatric Glioma.
    Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
    Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
    Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined BRAF
    Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T
    J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.
    Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
    BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
    Wang B; Zhang W; Zhang G; Kwong L; Lu H; Tan J; Sadek N; Xiao M; Zhang J; Labrie M; Randell S; Beroard A; Sugarman E; Rebecca VW; Wei Z; Lu Y; Mills GB; Field J; Villanueva J; Xu X; Herlyn M; Guo W
    Oncogene; 2021 Sep; 40(37):5590-5599. PubMed ID: 34304249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
    Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
    Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B
    BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained Tumor Control With MAPK Inhibition in
    Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
    Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
    Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.
    Takemoto M; Tanaka T; Tsuji R; Togashi Y; Higashi M; Fumino S; Tajiri T
    Biochem Biophys Res Commun; 2021 Sep; 570():41-46. PubMed ID: 34271435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
    Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
    Ernst T; Aebi S; Zander A; Zander T
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
    Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.